Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adrenocortical carcinoma.

Sanziana Roman1

  • 1Yale University School of Medicine, New Haven, Connecticut 06520, USA. sanziana.roman@yale.edu

Current Opinion in Oncology
|December 17, 2005
PubMed
Summary
This summary is machine-generated.

Adrenocortical carcinoma survival is poor, especially in adults. Pediatric virilizing tumors show better outcomes, but new treatments for adrenocortical carcinoma are urgently needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using the Perspectives of Advanced Practice Providers to Design Strategies to Increase Engagement of Surgical Patients in Advance Care Planning.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2025
Same author

Cancer-related Fear and Worry in Patients With Low-risk Thyroid Cancer: A Longitudinal Cohort Study.

The Journal of clinical endocrinology and metabolism·2024
Same author

Nerve monitoring in endocrine surgery: Practice patterns differ among surgeons for parathyroidectomy and thyroidectomy.

Surgery·2023
Same author

Invited commentary: Perspective of health equity in Endocrine Surgery.

Surgery·2023
Same author

Routine use of intraoperative nerve monitoring is associated with a reduced risk of vocal cord dysfunction after thyroid cancer surgery.

BMC surgery·2023
Same author

Disparities in advance care planning rates persist among emergency general surgery patients: Current state and recommendations for improvement.

The journal of trauma and acute care surgery·2023
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Adrenocortical carcinoma is a rare cancer with poor 5-year survival rates (20-45%).
  • Diagnosis often occurs at advanced stages, limiting treatment options.
  • Functional status of tumors impacts prognosis differently in adults versus pediatric patients.

Purpose of the Study:

  • To review recent advances in understanding adrenocortical carcinoma tumorigenesis.
  • To evaluate current diagnostic and therapeutic strategies.
  • To highlight the need for new treatment development.

Main Methods:

  • Review of recent scientific literature on adrenocortical carcinoma.
  • Analysis of studies on tumorigenesis, diagnostics, and treatment outcomes.

Related Experiment Videos

  • Synthesis of findings regarding surgical and adjuvant therapies.

    • Main Results:

    • Tumorigenesis research focuses on onco-developmental genes and adrenal paracrine/autocrine effects.
    • Positron emission scanning shows promise for diagnosing indeterminate adrenal masses.
    • Surgery is the primary treatment; mitotane remains the preferred adjuvant therapy with modest effects.

    Conclusions:

    • No significant treatment advances for adrenocortical carcinoma have been made.
    • Surgery is crucial for primary, recurrent, and select metastatic disease.
    • Establishment of multi-institutional registries and trials is essential for developing novel therapeutic strategies.